Sofinnova Ventures
Latest statistics and disclosures from Sofinnova Investments's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NTRA, VERA, NVO, AZN, IDYA, and represent 41.69% of Sofinnova Investments's stock portfolio.
- Added to shares of these 10 stocks: Bioage Labs (+$48M), INCY (+$47M), NVS (+$23M), JAZZ (+$21M), AXSM (+$20M), IDYA (+$19M), SLNO (+$17M), RYTM (+$15M), ELAN (+$9.6M), GH (+$9.3M).
- Started 12 new stock positions in JANX, BDX, RYTM, REPL, ILMN, NVS, INCY, GH, TMO, Bioage Labs. JAZZ, VIR.
- Reduced shares in these 10 stocks: QQQ (-$192M), ASND (-$100M), EW (-$67M), SYK (-$66M), , ALGN (-$53M), , ABT (-$41M), TGTX (-$35M), .
- Sold out of its positions in ABT, ALGN, ALNY, AMLX, ASND, AVTR, AXNX, BAX, CLDX, DXCM.
- Sofinnova Investments was a net seller of stock by $-714M.
- Sofinnova Investments has $1.3B in assets under management (AUM), dropping by -34.52%.
- Central Index Key (CIK): 0001631134
Tip: Access up to 7 years of quarterly data
Positions held by Sofinnova Ventures consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Sofinnova Investments
Sofinnova Investments holds 58 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Natera (NTRA) | 15.6 | $197M | 1.6M | 126.95 |
|
|
| Vera Therapeutics Cl A (VERA) | 9.8 | $124M | 2.8M | 44.20 |
|
|
| Novo-Nordisk A S Adr (NVO) | 6.9 | $87M | +11% | 726k | 119.07 |
|
| AstraZeneca Sponsored Adr (AZN) | 5.0 | $63M | 809k | 77.91 |
|
|
| Ideaya Biosciences (IDYA) | 4.4 | $55M | +51% | 1.7M | 31.68 |
|
| Elanco Animal Health (ELAN) | 4.1 | $52M | +22% | 3.5M | 14.69 |
|
| Bioage Labs | 3.8 | $48M | NEW | 2.3M | 20.80 |
|
| Axsome Therapeutics Put Option (AXSM) | 3.8 | $48M | +70% | 530k | 89.87 |
|
| Incyte Corporation (INCY) | 3.7 | $47M | NEW | 714k | 66.10 |
|
| Soleno Therapeutics (SLNO) | 3.6 | $45M | +59% | 886k | 50.49 |
|
| Rapport Therapeutics (RAPP) | 3.2 | $41M | +2% | 2.0M | 20.48 |
|
| Arrivent Biopharma (AVBP) | 3.2 | $40M | 1.7M | 23.50 |
|
|
| Y Mabs Therapeutics (YMAB) | 2.3 | $29M | 2.2M | 13.15 |
|
|
| Dyne Therapeutics (DYN) | 2.2 | $28M | -52% | 772k | 35.92 |
|
| Cogent Biosciences (COGT) | 1.9 | $25M | -18% | 2.3M | 10.80 |
|
| Savara (SVRA) | 1.9 | $24M | +2% | 5.7M | 4.24 |
|
| Novartis Sponsored Adr Put Option (NVS) | 1.8 | $23M | NEW | 200k | 115.02 |
|
| Inozyme Pharma (INZY) | 1.8 | $22M | 4.3M | 5.23 |
|
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 1.7 | $21M | NEW | 189k | 111.41 |
|
| Insmed Com Par $.01 (INSM) | 1.7 | $21M | +25% | 286k | 73.00 |
|
| Syndax Pharmaceuticals (SNDX) | 1.2 | $15M | -63% | 787k | 19.25 |
|
| Rhythm Pharmaceuticals (RYTM) | 1.2 | $15M | NEW | 277k | 52.39 |
|
| Edwards Lifesciences (EW) | 1.1 | $13M | -83% | 203k | 65.99 |
|
| Boston Scientific Corporation (BSX) | 0.9 | $11M | -20% | 136k | 83.80 |
|
| Pharvaris N V (PHVS) | 0.9 | $11M | 600k | 18.52 |
|
|
| Edgewise Therapeutics (EWTX) | 0.8 | $10M | -19% | 385k | 26.69 |
|
| Immunome (IMNM) | 0.8 | $9.9M | +3% | 677k | 14.62 |
|
| Guardant Health (GH) | 0.7 | $9.3M | NEW | 407k | 22.94 |
|
| Revolution Medicines (RVMD) | 0.7 | $9.2M | -55% | 203k | 45.35 |
|
| Inhibrx Biosciences (INBX) | 0.7 | $8.4M | +15% | 536k | 15.66 |
|
| Tg Therapeutics (TGTX) | 0.7 | $8.4M | -80% | 359k | 23.39 |
|
| Aerovate Therapeutics (AVTE) | 0.6 | $7.9M | 3.8M | 2.09 |
|
|
| Establishment Labs Holdings Ord (ESTA) | 0.6 | $7.9M | -57% | 182k | 43.27 |
|
| Marinus Pharmaceuticals (MRNS) | 0.6 | $7.7M | +3% | 4.4M | 1.76 |
|
| Janux Therapeutics (JANX) | 0.6 | $7.5M | NEW | 165k | 45.43 |
|
| Cabaletta Bio (CABA) | 0.6 | $7.2M | +25% | 1.5M | 4.72 |
|
| Achieve Life Sciences (ACHV) | 0.6 | $7.2M | +9% | 1.5M | 4.74 |
|
| Kura Oncology (KURA) | 0.5 | $5.8M | -64% | 297k | 19.54 |
|
| Phibro Animal Health Corp Cl A Com (PAHC) | 0.4 | $5.4M | 238k | 22.52 |
|
|
| Illumina (ILMN) | 0.4 | $5.3M | NEW | 41k | 130.41 |
|
| Erasca (ERAS) | 0.4 | $5.0M | +8% | 1.8M | 2.73 |
|
| Immatics SHS (IMTX) | 0.3 | $4.4M | -51% | 386k | 11.41 |
|
| Inari Medical Ord (NARI) | 0.3 | $3.7M | -42% | 90k | 41.24 |
|
| Becton, Dickinson and (BDX) | 0.3 | $3.7M | NEW | 15k | 241.10 |
|
| Nextcure (NXTC) | 0.3 | $3.7M | 2.7M | 1.37 |
|
|
| Thermo Fisher Scientific (TMO) | 0.3 | $3.6M | NEW | 5.8k | 618.57 |
|
| EXACT Sciences Corporation (EXAS) | 0.2 | $2.6M | -79% | 38k | 68.12 |
|
| Disc Medicine (IRON) | 0.2 | $2.0M | +41% | 41k | 49.14 |
|
| Bolt Biotherapeutics (BOLT) | 0.1 | $1.8M | 2.8M | 0.65 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.1 | $1.7M | +335% | 39k | 43.89 |
|
| Perspective Therapeutics (CATX) | 0.1 | $1.6M | -8% | 121k | 13.35 |
|
| Avidity Biosciences Ord (RNA) | 0.1 | $1.4M | +42% | 31k | 45.93 |
|
| Vir Biotechnology (VIR) | 0.1 | $968k | NEW | 129k | 7.49 |
|
| Astria Therapeutics (ATXS) | 0.1 | $943k | +41% | 86k | 11.01 |
|
| Immatics *w Exp 07/01/2025 (IMTXW) | 0.1 | $852k | +5% | 367k | 2.33 |
|
| Ikena Oncology (IKNA) | 0.1 | $662k | 383k | 1.73 |
|
|
| Replimune Group (REPL) | 0.0 | $528k | NEW | 48k | 10.96 |
|
| Pulmonx Corp (LUNG) | 0.0 | $517k | +3% | 62k | 8.29 |
|
Past Filings by Sofinnova Investments
SEC 13F filings are viewable for Sofinnova Investments going back to 2018
- Sofinnova Investments 2024 Q3 filed Nov. 13, 2024
- Sofinnova Investments 2023 Q4 restated filed Aug. 15, 2024
- Sofinnova Investments 2024 Q1 restated filed Aug. 14, 2024
- Sofinnova Investments 2024 Q2 filed Aug. 9, 2024
- Sofinnova Investments 2024 Q1 filed May 15, 2024
- Sofinnova Investments 2023 Q3 filed Nov. 14, 2023
- Sofinnova Investments 2023 Q2 filed Aug. 14, 2023
- Sofinnova Investments 2023 Q1 filed May 11, 2023
- Sofinnova Investments 2022 Q4 filed Feb. 14, 2023
- Sofinnova Investments 2022 Q3 filed Nov. 8, 2022
- Sofinnova Investments 2022 Q2 filed Aug. 15, 2022
- Sofinnova Investments 2022 Q1 filed May 16, 2022
- Sofinnova Investments 2021 Q4 filed Feb. 14, 2022
- Sofinnova Investments 2021 Q3 filed Nov. 15, 2021
- Sofinnova Investments 2021 Q2 filed Aug. 16, 2021
- Sofinnova Investments 2021 Q1 filed May 14, 2021